An endometrial biopsy is a procedure used for obtaining small and thin section of endometrial tissue, an inner most lining of uterus, for disease detection and testing. Clinically endometrial biopsy cannulae is used for the evaluation of infertility, amenorrhea, uterine cancer, abnormal uterine bleeding or endometrial infection. Endometrial biopsy cannulae are available in varying size. They are effective and affordable small medical device used for regular diagnostic practice.
Disease detection based on biopsy is gaining significant traction, owing to its accuracy, which is expected to drivie the endometrial biopsy cannulae market growth over the forecast period. For instance, according to National Cancer Institute, around 85% of endometrial cancer are diagnosed at earlier stage using endometrial sampling or biopsy. Moreover, increasing incidences of uterine related diseases are driving growth of the endometrial biopsy cannulae market.
Endometrial Biopsy Cannulae Market Dynamics
Increasing incidences of uterine cancer is the major factor propelling demand for endometrial biopsy cannulae, which in turn is driving growth of the endometrial biopsy cannulae market size. For instance, according to National Cancer Institute’s Surveillance, Epidemiology, and End Results Program, an estimated new cases of cancer to be reported in 2018 are 63,230, in the U.S., which comprises 26.0 cases per 100,000 women.
Furthermore, same source reported an estimated 2.9% of women are expected to have uterine cancer during their lifespan. Therefore, population at high risk of developing cancer frequently undergo cancer diagnosis, which is propelling demand for endometrial biopsy cannulae. According to American Cancer Society’s (ACS) publication, Cancer Facts & Figures 2018, around 92% of uterine cancer are observed in endometrial lining and high prevalence of obesity increases the risk of uterine cancer development proportionally.
Infertility is also diagnosed using biopsy and high prevalence of infertility related issues are also expected to fuel growth of the endometrial biopsy cannulae market over the forecast period. For instance, according to Maternal Health Task Force (MHTF), a project of the Women and Health Initiative at the Harvard T.H. Chan School of Public Health, 2017, nearly 50 million couples experience infertility, worldwide.
Abnormal uterine bleeding is also a significant clinical condition demanding for endometrial biopsy. According to Best Practice & Research. Clinical Obstetrics & Gynaecology, 2016, heavy menstrual bleeding affects 14-25% of women of the reproductive age. Moreover, it states that 800,000 women consult medical professional for abnormal uterine bleeding annually.
Increasing initiatives to create awareness among population for early detection of diseases such as cancer and its importance to reduce the morbidity are expected to boost the endometrial biopsy cannulae market. For instance, governments and non-governmental organizations organize programs to spread awareness about early detection of cancer and its importance and also recommend for the periodic check-ups for cancer. Furthermore, consultation with respect to infertility are increasing at fast pace, owing to increasing awareness, which in turn is propelling the market growth.
Endometritis, uterine infection, is another common condition in the low income economies, which demands for clinical attention. For instance, according to Clinical and Experimental Reproductive Medicine, 2016, the prevalence of chronic endometritis is around 10% of the population.
However, endometrial biopsy cannulae market growth is expected to be hindered by complications associated with the product use such as uterine or cervical injury, pelvic infection, vagal reaction, incomplete evacuation, or acute hematometra. Moreover, alternative methods for biopsy such as imagining technics or vaginal fine-needle aspiration is also expected to restrain the market growth.
Endometrial Biopsy Cannulae Market - Regional Analysis
On the basis of region, the global endometrial biopsy cannulae market is segmented by Coherent Market Insights into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa regions. North America endometrial biopsy cannulae market holds dominant in the regional segment. The reason attributing to the dominancy of North American market is increasing uterine cancer incidence. For instance, according to National Cancer Institute, the incidence of uterine cancer increased by 1% per year in the time span of 2005 to 2014 in white women. However, Asia Pacific and Africa provides good opportunity for the market players to expand their product range to fulfil the unmet medical needs in low income economies.
Major players in the global endometrial biopsy cannulae market include Medline Industries, Inc., CooperSurgical, Inc., MedGyn Products, Inc., Gyneas, Andemed, Nuode, Saipu, Micromed, and Panpac Medical & RI.MOS.
Endometrial Biopsy Cannulae Market Taxonomy
Based on product type:
- Rigid Endometrial Biopsy Cannulae
- Flexible Endometrial Biopsy Cannulae
Based on end user:
- Diagnostic Centers
- Specialty Clinics
Based on region:
- North America
- Latin America
- Asia Pacific
- Middle East